Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven metastatic melanoma Measurable disease
HLA-A2 01 phenotype No active CNS or hepatic metastases

PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Karnofsky 80-100% Life
expectancy: Not specified Hematopoietic: Normal CD4 and CD8 T cell numbers by flow
cytometry Lactic dehydrogenase less than 2 times normal Hepatic: No viral hepatitis Renal:
Not specified Cardiovascular: No prior venous thrombosis, angina pectoris, or congestive
heart failure Pulmonary: No prior asthma Immunologic: Positive intradermal skin test for
mumps, histoplasmosis, or streptokinase antigen Immunoglobulin levels normal No prior
autoimmune disease (lupus erythematosus, rheumatoid arthritis, or thyroiditis) No allergy
to tetanus toxoid or influenza vaccine No sensitivity to E. coli drug preparations Other:
Not pregnant or nursing Fertile patients must use effective contraception HIV negative No
active infection

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior interferon At
least 8 weeks since prior interleukin-2 Chemotherapy: No more than 3 prior courses of
cytotoxic chemotherapy At least 8 weeks since prior chemotherapy Endocrine therapy: No
concurrent corticosteroids Radiotherapy: Not specified Surgery: Not specified Other: No
other concurrent immunosuppressive agents